The injectable formulation of Olfen-75 is primarily used to provide supportive relief in acute clinical situations marked by heightened pain, swelling, and inflammation. The medicine is intended for symptomatic relief in cases where short-term symptomatic assistance is needed.

The medication is applicable within clinical settings that involve acute or disruptive symptom patterns, including flare-ups of rheumatoid arthritis and osteoarthritis, management of severe pain associated with renal colic and gouty arthritis, and management of discomfort after trauma or surgery. This supportive relief may assist with maintaining functional stability and contributes to easing the overall symptom load during difficult episodes.

“A key benefit supports the patient during difficult episodes and contributes to improved day-to-day comfort.”

Relief of Acute Musculoskeletal and Joint Pain

This domain helps address symptom clusters that may become intense or disruptive, such as symptoms of pronounced discomfort, stiffness, and inflammation. The benefit supports the patient during difficult episodes and contributes to improved day-to-day comfort.

---

Quick Fact: Relief for Acute Pain & Inflammation
Symptom Focus	Pronounced discomfort, swelling, stiffness
Severity Relevance	Acute or episodic symptoms of increased discomfort
Core Benefit	Supportive relief and assistance with functional stability
Context of Use	Post-trauma, post-op, or acute flare-ups

Eligibility Profile: Who Can and Cannot Use Olfen-75?

Olfen-75 eligibility is strictly determined by regulatory rules governing the use of the systemic Nonsteroidal Anti-inflammatory Drug (NSAID) component, Diclofenac. The medicine is primarily approved for use in adults for acute pain management.

---

Absolute Contraindications

Use is prohibited in patients with a known hypersensitivity to any NSAID, a history of aspirin-sensitive asthma, or current active gastrointestinal ulceration, bleeding, or perforation. It is also contraindicated in patients with established severe cardiac failure (NYHA Class II–IV), severe renal or hepatic failure, established ischemic heart disease, and those receiving treatment for perioperative pain in the setting of Coronary Artery Bypass Graft (CABG) surgery.

---

Restrictions and Conditional Use

The medicine is generally not recommended for children and adolescents (typically under 14 to 18 years, depending on the label) as safety and efficacy are not established. Women in the last trimester of pregnancy are contraindicated from use. Special caution and monitoring are required for elderly patients, those with mild-to-moderate renal or hepatic impairment, and patients with significant cardiovascular risk factors or pre-existing inflammatory bowel diseases.

Interactions with Other Medicines and Products

The interaction profile of Olfen-75 (diclofenac) is primarily defined by Pharmacodynamic Synergism and Exposure Modification as documented in regulatory information. Co-administration with certain substances can lead to additive risks or altered drug concentrations.

---

Documented Pharmacological Interactions

Interaction Type	Interacting Product Category	Practical Implication
Pharmacodynamic Synergism	Anticoagulants, Antiplatelet agents	Increased risk of serious bleeding.
	Diuretics, ACE Inhibitors	Reduced antihypertensive effect; increased risk of kidney function impairment.
	Corticosteroids, SSRIs	Increased risk of gastrointestinal ulceration and bleeding.
Exposure Modification	Digoxin, Lithium, Methotrexate	Olfen-75 can increase the plasma concentrations of these medicines.
	Strong CYP2C9 Inhibitors (e.g., Voriconazole)	Increased exposure and concentration of Olfen-75.

---

Required Constraints and Considerations

Co-administration with other systemic NSAIDs (including COX-2 inhibitors) is generally contraindicated due to additive adverse effect risks. Patients taking strong CYP2C9 inhibitors should be monitored for increased Olfen-75 exposure. Substances like Colestipol or Cholestyramine may reduce Olfen-75 absorption, requiring doses to be spaced hours apart. Special caution regarding potential nephrotoxicity is noted for elderly patients and those with existing renal impairment when using Olfen-75 with agents like cyclosporine or diuretics.

How Olfen-75 Works

Olfen-75 (diclofenac sodium) initiates an intervention via enzyme inhibition that modulates specific signaling pathways within the body. Its action is centered on inhibiting the Cyclooxygenase (COX) enzyme system, which includes both the COX-1 and COX-2 isoforms.

This primary mechanistic activity directly blocks the initial step in the synthesis of specific lipid mediators, initiating a molecular cascade. By inhibiting COX, Olfen-75 reduces the production of prostaglandins and other eicosanoids. This modulation results in the establishment of a state of reduced eicosanoid synthesis within the targeted pathways, consequentially reducing the concentration and influence of these mediators at the cellular level.

The drug's unique sustained-release formulation provides a crucial mechanistic feature, ensuring the active substance maintains continuous concentrations at the enzyme targets over an extended duration. This continuous presence sustains the resulting state of enzyme inhibition over the duration of the release profile.

How Olfen-75 is Used

The administration of Olfen-75, an injectable solution containing 75 mg of Diclofenac Sodium and Lidocaine Hydrochloride, is intended for acute, short-term usage. The fundamental principle is to administer the lowest effective dose for the shortest duration necessary to address acute symptoms, adhering to limitations set forth in the prescribing information.

---

Administration Routes and Standard Dosing

The official labeling permits two primary parenteral routes: Intramuscular (IM) injection and Intravenous (IV) infusion. The medicine is strictly not for intravenous bolus injection.

Administration Route	Standard Adult Usage Pattern
Intramuscular (IM)	Standard dose is 75 mg once daily, delivered as a deep intragluteal injection. The dose may be increased to 150 mg (two 75 mg ampoules) in severe cases, requiring injections into alternating sites.
Intravenous (IV)	Used via infusion only, typically over 30 minutes to 2 hours, for pain management. The solution must be diluted and buffered with sodium bicarbonate before use.

---

Duration and Specific Constraints

The injectable form is reserved for a very limited course and must not be administered for more than two days. If continued systemic therapy is required beyond this period, treatment should be switched to oral or rectal dosage forms of diclofenac. The absolute maximum daily dose from all sources (injectable, oral, or rectal) must not exceed 150 mg.

For older adults, the official instruction emphasizes using the lowest effective dose for the shortest duration. The injectable formulation is not suitable for use in children.

Research evidence / Overview of studies for Olfen-75

Evidence for Use in Acute Postoperative and Post-Trauma Pain

Research exploring how this medicine was studied for pain after surgery or physical trauma primarily comes from short-term Randomized Controlled Trials (RCTs) in adult patients. Researchers monitored patient-reported outcomes describing perceived discomfort, using scales to measure pain intensity and tracking the requirement for supplementary pain medication. Studies reported patterns related to lower use of rescue pain medication within the first day compared to placebo, and findings describe outcomes related to acute changes in pain scores. Evidence is concentrated on the immediate, acute phase; follow-up durations were limited, and comparative evidence against the single active ingredient is lacking.

---

Evidence for Use in Acute Musculoskeletal Disorders

This medicine was studied for conditions associated with acute or disruptive episodes, such as arthritis and severe back pain. The evidence includes RCTs and data from studies on the general pharmacological class. Research explored outcomes related to daily functioning or activity level and changes in patient-reported pain scores over periods that may extend up to a month. Studies monitored outcomes linked to inflammatory states. The evidence quality varies across studies due to the wide range of diagnoses included, and the contribution of the local anesthetic component to long-term management is not fully established.

---

Evidence for Use in Managing Intense, Acute Pain Episodes

The evidence stems from studies focusing on episodes where symptoms become more noticeable, such as renal colic or acute migraine. This medicine was evaluated in research contexts involving fluctuating symptoms, examining outcomes including the timing of the observed response and changes in pain intensity shortly after administration. Data show patterns related to measurements of a change in pain intensity scores during the acute care setting. Follow-up durations were limited, as the studies were designed for immediate resolution, and data are still emerging for use across a wide range of acute pain syndromes.

---

Long-Term Studies and Follow-up Durations

The available research primarily focuses on the way the medicine was observed in acute, short-duration episodes. The follow-up durations were limited across the main clinical trials. There is limited information for long-term outcomes or how the effect may be sustained. Long-term effects are not fully established regarding the use of this specific injectable formulation for maintenance therapy.

---

Evidence in Special Populations and Subgroups

Research typically focuses on generally healthy adults. Data for certain groups remain insufficient. There is limited specific information from key trials regarding research exploring outcomes related to older adults or in patients with significant co-existing medical conditions. The sample sizes were modest or the data was not specifically isolated for these subgroups.

---

What Remains Uncertain About the Research for Olfen-75

Evidence highlights what is known—and what is still uncertain. A primary limitation is the comparative evidence is lacking to clarify outcomes related to the dual-active formulation versus the single active ingredient administered alone. Furthermore, certainty remains low regarding outcomes beyond the immediate, acute treatment period, as long-term effects are not fully established.

Common questions about Olfen-75 (FAQ)

Q: How quickly does Olfen-75 typically start to work for pain relief?

A: Studies and official information indicate that the injectable formulation is designed for rapid relief. The onset of pain relief typically occurs within 15 to 30 minutes after intravenous administration or within 30 minutes after intramuscular administration.

Q: How long does the effect of one dose of Olfen-75 usually last?

A: The duration of the pain-relieving effect for a single dose of the active ingredient, diclofenac, is generally described in studies as lasting 4 to 6 hours. This sustained effect is part of its pharmacological profile as an anti-inflammatory medicine.

Q: Can I take Olfen-75 if I am also taking an anti-depressant?

A: Regulatory documents indicate a potential interaction between the diclofenac component of Olfen-75 and certain categories of antidepressants, such as Selective Serotonin Reuptake Inhibitors (SSRIs). Co-administration may increase the risk of serious gastrointestinal bleeding. Information regarding all current medications is typically reviewed with a healthcare provider.

Q: Is it safe to drink alcohol while using Olfen-75?

A: Official safety warnings describe alcohol consumption as a factor that can increase the likelihood of serious gastrointestinal complications, such as bleeding or ulcers, when combined with diclofenac. Official documentation notes that combining alcohol with the drug may contribute to existing concerns related to liver function.

Q: Is Olfen-75 a habit-forming or addictive medicine?

A: The regulatory classification identifies the active ingredient, diclofenac, as a Nonsteroidal Anti-inflammatory Drug (NSAID). NSAIDs are not classified as controlled substances and are not described as being habit-forming or addictive in official regulatory labeling.

Q: Are there special considerations for older patients using Olfen-75?

A: Official product information emphasizes that the injectable solution should be used with particular caution in older adults. This is due to an increased susceptibility to adverse reactions, with regulatory guidance recommending the lowest effective dose for the shortest possible duration.

Q: Why is Olfen-75 sometimes prescribed as a delayed-release or enteric-coated tablet?

A: Although Olfen-75 is an injectable solution, other oral forms of diclofenac are often formulated with enteric or delayed release coatings. This design is intended to help protect the stomach lining from direct irritation by the medication and to delay its absorption into the body.

Q: Is it necessary to have regular check-ups while taking Olfen-75 long-term?

A: Regulatory information advises that patients receiving long-term treatment with diclofenac should be regularly reviewed to assess the medicine's effectiveness and monitor for adverse effects. Regulatory documents mention that monitoring of parameters such as blood pressure, kidney function, and blood levels is often considered during long-term use.

Q: What is the difference in how Olfen-75 works compared to acetaminophen?

A: The mechanism of action for the anti-inflammatory component of Olfen-75 (diclofenac) is described as inhibiting both COX-1 and COX-2 enzymes. Acetaminophen also affects cyclooxygenase, but its anti-inflammatory effect is described as being dependent on the chemical environment within the inflamed tissues.

Q: Can Olfen-75 affect my ability to drive or operate machinery?

A: Diclofenac labeling typically includes a warning that patients who experience side effects such as dizziness, vertigo, somnolence, or vision disturbances should avoid driving or operating complex machinery. Labeling typically indicates that individuals experiencing these effects should avoid driving or operating complex machinery.

Q: Can Olfen-75 be used by people who have asthma?

A: The medicine is strictly prohibited (contraindicated) for use in patients who have a history of asthma, hives, or allergic-type reactions after taking aspirin or other Nonsteroidal Anti-inflammatory Drugs (NSAIDs).

Q: Does using Olfen-75 affect fertility or conception?

A: Regulatory-based guidance states that anti-inflammatory medicines containing diclofenac may affect ovulation if taken in high doses or for a long time. This effect could make conception more difficult for women attempting to become pregnant.

Q: Can Olfen-75 make me more sensitive to the sun?

A: Diclofenac is described in some official product information as having a phototoxic potential. This means it may cause certain skin reactions, such as severe sunburn, upon exposure to ultraviolet (UV) radiation from sunlight.

Q: What happens if I miss taking a dose of Olfen-75?

A: Patient information for diclofenac states that if a dose is forgotten, the next scheduled dose should be taken at the usual time. Official guidance notes that a double dose should not be taken to compensate for a forgotten one.

Q: Are there certain foods or supplements that should be avoided with Olfen-75?

A: While the injectable formulation avoids interaction with foods, general safety guidance for diclofenac indicates potential for interactions with certain supplements, particularly herbal products, due to increased bleeding risk. The disclosure of all supplements being taken is typically recommended.

Q: Do children or teenagers ever use Olfen-75?

A: Official information for the Olfen-75 injectable formulation states that it is not suitable for use in children. The safety and efficacy for this specific product have not been established in the pediatric population.

Q: Can Olfen-75 interact with natural supplements or herbal products?

A: Official patient information notes that there is limited safety information regarding the co-administration of diclofenac with various herbal remedies and natural supplements. This suggests that the use of such products is typically reviewed with a healthcare provider.

Q: Is it normal to feel a change in my appetite after starting Olfen-75?

A: Official side effect lists for diclofenac include reports of taste disturbance in some individuals. Such changes in taste may be related to or influence a patient's normal appetite.

Q: Does Olfen-75 relieve swelling as well as pain?

A: Yes, the pharmacological classification of diclofenac as a Nonsteroidal Anti-inflammatory Drug (NSAID) means its intended function is to reduce both swelling (inflammation) and pain, providing a dual therapeutic effect.

How to Store and Dispose of Olfen-75?

The official storage and disposal requirements for Olfen-75 (Diclofenac Sodium/Lidocaine HCl injectable solution) are established by regulatory authorities to ensure product stability and safety.

---

Storage Requirements

Condition	Requirement
Temperature	Store below 30°C. Must not be frozen.
Protection	Must be kept in the original package to protect from light and moisture.
Safety	Keep all medicine out of the sight and reach of children and pets.

---

Disposal Instructions

Unused or expired Olfen-75 must not be disposed of via household waste or wastewater. The proper disposal method is through an authorized pharmaceutical take-back scheme or by following specific local requirements for medicinal products, as mandated by regulatory guidelines. This ensures the medicine is discarded safely and prevents environmental contamination.